127 related articles for article (PubMed ID: 7444151)
1. N-(Phosphonacetyl)-L-aspartate (PALA): current status.
Rozencweig M; Abele R; Piccart M; Von Hoff DD; Muggia FM
Recent Results Cancer Res; 1980; 74():72-7. PubMed ID: 7444151
[TBL] [Abstract][Full Text] [Related]
2. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
3. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Johnson RK; Swyryd EA; Stark GR
Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
[No Abstract] [Full Text] [Related]
4. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
5. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
6. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
10. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Johnson RK; Inouye T; Goldin A; Stark GR
Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
Roboz J; Suzuki R; Rose E
J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
17. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
[TBL] [Abstract][Full Text] [Related]
18. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
White JC; Hines LH
Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
[TBL] [Abstract][Full Text] [Related]
19. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
[TBL] [Abstract][Full Text] [Related]
20. Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography.
Grem JL; Drake JC; Allegra CJ
Anticancer Drugs; 1993 Oct; 4(5):545-54. PubMed ID: 8292811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
